



IFW

**Certification under 37 CFR 1.8(a)**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with The United States Postal Service with sufficient postage as first class mail in an envelope addressed to THE COMMISSIONER FOR PATENTS, P.O. Box 1450, Alexandria, VA 22313-1450 on August 24, 2007.

Brian W. Hameder (Reg. No. 45,613)  
Name

  
Signature

DOCKET: CU-4511

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Yves De Koninck et al

Serial No.: 10/556,221

Group Art Unit:

Filed: November 9, 2005

Examiner:


For: CNS CHLORIDE MODULATION AND USES THEREOF


THE COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT WITHIN THREE MONTHS OF FILING OR BEFORE MAILING OF FIRST OFFICE ACTION**

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of the first Office Action on the merits, whichever event occurs last. 37 CFR 1.97(b).

Date: August 24, 2007


  
Signature of Attorney  
Brian W. Hameder  
Ladas & Parry LLP  
224 South Michigan Avenue  
Chicago Illinois 60604  
Tel. No. (312) 427-1300  
Reg. No. 45613



**Certification under 37 CFR 1.8(a)**

hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with The United States Postal Service with sufficient postage as first class mail in an envelope addressed to THE COMMISSIONER FOR PATENTS, P.O. Box 1450, Alexandria, VA 22313-1450 on August 24, 2007.

Brian W. Hameder (Reg. No. 45,613)  
Name

  
Signature

DOCKET: CU-4511

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Yves De Koninck et al

Serial No.: 10/556,221

Group Art Unit:

Filed: November 9, 2005

Examiner:

For: CNS CHLORIDE MODULATION AND USES THEREOF

THE COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Applicants submit herewith patents, publications or other information of which the applicants are aware, which may be material to the examination of this application and in respect of which there may be a duty to disclose under 37 CFR 1.56.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

The references submitted herein are listed on PTO-1449 form (modified) enclosed herewith. A copy of each reference listed is being furnished except any duplicate or cumulative patents or publications specified otherwise. Also, if the present application was filed after June 30, 2003, copies of US patents or published applications are not submitted in accordance with the USPTO Rule changes.

A translation of any foreign language reference, if any, is indicated in PTO-1449 form and being submitted herein if it is readily available. Otherwise it should be construed that such translation is not readily available.

Additional comments, if any, on the relevance of each reference listed are provided as follows:

**Also submitted herein is a copy of the PCT Search Report which satisfies the requirement for a translation or concise explanation of any non-English reference cited therein, as provided in MPEP §609 A(3).**

The Statement is made on the basis of the information:

<u>          </u>	supplied by the inventor(s);
<u>  X  </u>	supplied by an individual associated with the filing and prosecution
<u>          </u>	of this application (37 CFR 1.56(c)); or
<u>          </u>	in the attorney's file.

Respectfully submitted,

Date: August 24, 2007



Signature of Attorney  
Brian W. Hameder  
Ladas & Parry LLP  
224 South Michigan Avenue  
Chicago Illinois 60604  
Tel. No. (312) 427-1300  
Reg. No. 45613

Form PTO-1449 (Modified)

FORM PTO-1449  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (37 CFR 1.98(b))	ATTY. DOCKET NO.	SERIAL NO.
	CU-4511	10/556,221
	APPLICANT Yves De KONINCK et al	
	FILING DATE	GROUP
	November 9, 2005	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT DOCUMENT	ISSUE/PUB DATE	PATENTEE	CLASS	SUB- CLASS	FILING DATE
	2002/0173478	11/21/02	Gewirtz			
	2002/0132788	09/19/02	Lewis et al			
	5,135,917	08/04/92	Burch			
	5,098,890	03/24/92	Gewirtz et al			
	5,087,617	02/11/92	Smith			
	5,166,195	11/24/92	Ecker			
	5,004,810	04/02/91	Draper			
	5,194,428	03/16/93	Agrawal et al			
	4,806,463	02/21/89	Goodchild et al			
	5,286,717	02/15/94	Cohen et al			
	5,276,019	01/04/94	Cohen et al			
	5,264,423	11/23/93	Cohen et al			
	5,932,435	08/03/99	Atkins et al			
	5,034,506	07/23/91	Summerton et al			
	5,539,082	07/23/96	Nielsen et al			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

EXAMINER INITIAL	DOCUMENT NUMBER	PUBL. DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB- CLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Place of publication)

	Lee et al. 2002. "Cdk4 and p27 <sup>Kip1</sup> play a role in PLC- 1-mediated mitogenic signaling pathway of 18 kDa FGF-2 in corneal endothelial cells." <i>Mol. Vis.</i> 8:17-25.
	Monick et al. 1999. "A Phosphatidylcholine-Specific Phospholipase C Regulates Activation of p42/44 Mitogen-Activated Protein Kinases in Lipopolysaccharide-stimulated Human Alveolar Macrophages." <i>J. Immunol.</i> 162:3005-3012.
	Maragoudakis et al. 1993. "Basement membrane biosynthesis as a target for developing inhibitors of angiogenesis with anti-tumor properties." <i>Kidney Int.</i> , 43(1):147-150.
	Schutze et al. 1992. "TNF Activates NF-kB by Phosphatidylcholine-Specific Phospholipase C-Induced 'Acidic' Sphingomyelin Breakdown." <i>Cell.</i> 71:765-776.
	Muller-Decker, K. 1989. "Interruption of TPA-Induced Signals by an Antiviral and Antitumoral Xanthate Compound: Inhibition of a Phospholipase C-Type Reaction." <i>Biochem. Biophys. Res. Commun.</i> 162:198-205.
	Sauer et al. 1984. "DNA and RNA virus species are inhibited by xanthates, a class of antiviral compounds with unique properties." <i>Proc. Natl. Acad. Sci. USA.</i> 81:3263-3267.
	Carpenter et al. 1999. "Phospholipase C- as a Signal-Transducing Element." <i>Experimental Cell Research.</i> 253:15-24.
	Noh et al. 1998. "Expression of Phospholipase C- 1 and its Transcriptional Regulators in Breast Cancer Tissues." <i>Anticancer Research.</i> 18:2643-2648.

	Shu et al. 2002. "Regulation of Phospholipase C- Activity by Glycosphingolipids." <i>J. Biol. Chem.</i> 277(21):18447-18453.
	Mosconi et al. 1996. "Fixed-diameter polyethylene cuffs applied to the rat sciatic nerve induce a painful neuropathy: ultrastructural morphometric analysis of axonal alterations." <i>Pain.</i> 64:37-57.
	Chaplan et al. 1994. "Quantitative assessment of tactile allodynia in the rat paw." <i>J. Neurosci. Methods</i> , 53:55-63.
	Karim, et al. 2001. "Metabotropic Glutamate Receptor Subtypes 1 and 5 Are Activators of Extracellular Signal-Regulated Kinase Signaling Required for Inflammatory Pain in Mice." <i>J. Neurosci.</i> 3771-3779, Vol. 21(11)
	Galeotti et al. "The Phospholipase C-IP <sub>3</sub> Pathway is Involved in Muscarinic Antinociception." <i>Neuropsychopharmacol</i> , 2003, pp. 888-897. Vol. 28.
	Smith et al. 1999. "Involvement of phospholipid signal transduction pathways in morphine tolerance in mice." <i>Br. J. Pharmacol</i> , 2003, pp. 220-226, Vol. 128.
	Xie, et al. "Phospholipase C- 1 Is Required for Calcium-induced Keratinocyte Differentiation." <i>J. Biol. Chem.</i> 1999. Vol. 274(29). pp.20421-20424.
	Smith et al "Inhibition of Serum- and Ras-Stimulated DNA Synthesis by Antibodies to Phospholipase C." <i>Science</i> . 1990. Vol. 247. pp.1074-1077.
	Buckley et al. "Identification of Phospholipase C- 1 as a Mitogen-activated Protein Kinase Substrate." <i>J. Biol. Chem.</i> 2004. Vol. 279(40). pp.41807-41814.
	Rhee. "Regulation of Phosphoinositide-Specific Phospholipase C." <i>Annu. Rev. Biochem.</i> 2001. Vol. 70. pp.281-312.

(Form PTO-1449)